Dr Pavlick On Adjuvant Immunotherapy Dr Pavlick On Adjuvant Immunotherapy

Thomas Eigentler, MD, University of Tübingen, Tübingen, Germany, comments on the results of a key clinical trial presented at ... Vishal Patel, MD, FAAD, FACMS, George Washington University (GW), Washington, DC, comments on the potential of Jason Luke, MD, FACP, UPMC Hillman Cancer Center, Pittsburgh, PA, explores immune-related adverse events (irAEs) ... In this segment, the panelists discuss available evidence for Paul Nghiem, MD, PhD, University of Washington Medical Center, Seattle, WA, discusses the use of Great strides have been made in the treatment of advanced melanoma; these developments are now being translated into the ...

Francesco Guerrera, MD, University of Turin, Turin, Italy, provides an overview of a meta-analysis assessing adherence to ... In this segment, panelists discuss the important role that ipilimumab will continues to have as a treatment for patients with ... Andrea Apolo, MD, National Cancer Institute, Bethesda, MD, comments on the extended follow-up disease-free survival (DFS) ... Jason Luke, MD, FACP, University of Pittsburgh, Pittsburgh, PA, discusses unanswered questions regarding the use of Joaquim Bellmunt, MD, PhD, Beth Israel Deaconess Medical Center, Boston, MA, talks on the role of Jason J. Luke, MD, FACP, University of Pittsburgh, Pittsburgh, PA, summarises the KEYNOTE-716 trial (NCT03553836) ...

Presentation by John Kirkwood, MD, University of Pittsburgh Medical Center. Presented at Chair & Moderator, Prof. Solange Peters, MD, PhD, Mark M. Awad, MD, PhD, and Jonathan D. Spicer, MD, PhD, FRCSC, discuss ...